
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
Dr Shroff, GP in Nottingham, demonstrates the excision of a basal cell carcinoma.
Dr Shroff, GP in Nottingham, demonstrates the excision of a basal cell carcinoma.
Video created by